跳至主要内容
临床试验/NCT00816712
NCT00816712已完成1 期

A Randomized, Single-Blind, Placebo-Controlled, Single-dose, Parallel Design Study to Evaluate the Effect of Testosterone on Muscle Fractional Synthetic Rate (FSR)

Merck Sharp & Dohme LLC0 个研究点目标入组 28 人开始时间: 2008年1月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
28
主要终点
Thigh (vastus lateralis) muscle protein fractional synthetic rate one week after dosing with testosterone.

研究概览

简要总结

This is a study to evaluate the use of fractional synthetic rate as an early biomarker of muscle anabolism (muscle build-up).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
60 Years 至 70 Years(Adult, Older Adult)
性别
Male
接受健康志愿者
是

入选标准

  • •Subject is weight stable over the past 3 months
  • •Patient agrees to refrain from consumption of alcohol from 48 hours prior to entering the study
  • •Subject agrees to follow the study restriction of no caffeine while on study
  • •Patient agrees to following the meat-free controlled protein weight-maintaining diet
  • •Patient is willing to avoid strenuous physical activity
  • •Patient has been a nonsmoker for at least 6 months prior to study start

排除标准

  • •Subject is currently a regular user of any illicit drugs
  • •Subject has taken androgenic steroids in the previous 12 months
  • •Subject has participated in sports events, resistance exercise training or heavy exercise in the previous month
  • •Subject has prostate cancer
  • •Subject has a history of cancer except basal-cell tumors
  • •Subject has been diagnosed with HIV
  • •Subject has been diagnosed with Hepatitis B or C
  • •Subject uses certain anti-inflammatory drugs such as ibuprofen, arcoxia or celecoxib
  • •Subject uses a blood anticoagulant, such as Coumadin (Warfarin) or high doses of aspirin
  • •Subject is currently taking over the counter supplements such as "muscle builders" or "fat burners"
  • •Subject has an allergy or hypersensitivity to intramuscular testosterone
  • •Subject has sciatica
  • •Subject has donated blood products or has had phlebotomy within 2 months of signing informed consent
  • •Subject has undergone a surgical procedure within 1 month of signing informed consent
  • •Subject is currently participating or has participated in a study with an investigational drug or device

研究组 & 干预措施

A

Active Comparator

Testosterone - 300 mg IM

干预措施: Comparator: Testosterone 300 mg, intramuscular injection (Drug)

B

Active Comparator

Testosterone - 100 mg IM

干预措施: Comparator: Testosterone 100 mg, Intramuscular injection (Drug)

C

Placebo Comparator

Placebo - IM

干预措施: Comparator: Placebo given by Intramuscular Injection (Drug)

结局指标

主要结局

Thigh (vastus lateralis) muscle protein fractional synthetic rate one week after dosing with testosterone.

时间窗: One week

次要结局

  • Variability in the muscle fractional synthetic rate measurements.(One week)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验